{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:56:30Z","timestamp":1785761790705,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,29]]},"DOI":"10.7759\/cureus.98075","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T13:30:16Z","timestamp":1764423016000},"source":"Crossref","is-referenced-by-count":2,"title":["Fulminant Immune Checkpoint Inhibitor-Induced Myocarditis and Complete Heart Block in Advanced Melanoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Bakr","family":"Alhayek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Affan","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sepulveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Ramsakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109881","article-title":"Nivolumab plus ipilimumab combination therapy in cancer: current evidence to date","volume":"117","author":"Nikoo M","year":"2023","unstructured":"Nikoo M, Rabiee F, Mohebbi H, et al.. Nivolumab plus ipilimumab combination therapy in cancer: current evidence to date. Int Immunopharmacol. 2023, 117:109881. 10.1016\/j.intimp.2023.109881","journal-title":"Int Immunopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch9","article-title":"Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application","author":"Rausch MP","year":"2017","unstructured":"Rausch MP, Hastings KT. Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application. Cutaneous Melanoma: Etiology and Therapy. Codon Publications, 2017. 121-42. 10.15586\/codon.cutaneousmelanoma.2017.ch9"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940127","article-title":"Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors","volume":"12","author":"Irabor OC","year":"2022","unstructured":"Irabor OC, Nelson N, Shah Y, et al.. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Front Oncol. 2022, 12:940127. 10.3389\/fonc.2022.940127","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645245","article-title":"Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"11","author":"Hu J","year":"2021","unstructured":"Hu J, Tian R, Ma Y, Zhen H, Ma X, Su Q, Cao B. Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and meta-analysis. Front Oncol. 2021, 11:645245. 10.3389\/fonc.2021.645245","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi G","year":"2017","unstructured":"Varricchi G, Galdiero MR, Marone G, et al.. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017, 2:e000247. 10.1136\/esmoopen-2017-000247","journal-title":"ESMO Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral T","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A, et al.. Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025, 36:10-30. 10.1016\/j.annonc.2024.11.006","journal-title":"Ann Oncol"},{"key":"ref9","article-title":"Electrocardiogram","author":"Sattar Y","year":"2025","unstructured":"Sattar Y, Chhabra L. Electrocardiogram. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref10","article-title":"Left ventricular ejection fraction","author":"Shams P","year":"2025","unstructured":"Shams P, Goyal A, Makaryus AN. Left ventricular ejection fraction. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon AR","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018, 19:e447-58. 10.1016\/S1470-2045(18)30457-1","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00715-5","article-title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","volume":"24","author":"Munir AZ","year":"2024","unstructured":"Munir AZ, Gutierrez A, Qin J, Lichtman AH, Moslehi JJ. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart. Nat Rev Cancer. 2024, 24:540-53. 10.1038\/s41568-024-00715-5","journal-title":"Nat Rev Cancer"},{"key":"ref15","article-title":"Arrhythmias","author":"Desai DS","year":"2023","unstructured":"Desai DS, Hajouli S. Arrhythmias. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases","volume":"13","author":"Zotova L","year":"2023","unstructured":"Zotova L. Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases. Diagnostics (Basel). 2023, 13:1243. 10.3390\/diagnostics13071243","journal-title":"Diagnostics (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-64. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu JR","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019, 115:854-68. 10.1093\/cvr\/cvz026","journal-title":"Cardiovasc Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2022.03.003","article-title":"Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis","volume":"115","author":"Power JR","year":"2022","unstructured":"Power JR, Alexandre J, Choudhary A, et al.. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Arch Cardiovasc Dis. 2022, 115:315-30. 10.1016\/j.acvd.2022.03.003","journal-title":"Arch Cardiovasc Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-023-00185-y","article-title":"Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis","volume":"9","author":"O'Shea MP","year":"2023","unstructured":"O'Shea MP, Karikalan SA, Yusuf A, et al.. Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis. Cardiooncology. 2023, 9:34. 10.1186\/s40959-023-00185-y","journal-title":"Cardiooncology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101478","article-title":"Electrocardiographic features of immune checkpoint inhibitor-associated myocarditis","volume":"48","author":"Song W","year":"2023","unstructured":"Song W, Zheng Y, Dong M, et al.. Electrocardiographic features of immune checkpoint inhibitor-associated myocarditis. Curr Probl Cardiol. 2023, 48:101478. 10.1016\/j.cpcardiol.2022.101478","journal-title":"Curr Probl Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.103187","article-title":"Pacing solutions for immune checkpoint myocarditis and associated conduction disorders","volume":"30","author":"Palaskas NL","year":"2025","unstructured":"Palaskas NL, King NE, Ostos-Mendoza KC, et al.. Pacing solutions for immune checkpoint myocarditis and associated conduction disorders. JACC Case Rep. 2025, 30:103187. 10.1016\/j.jaccas.2024.103187","journal-title":"JACC Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2024-2480","article-title":"Abstract 2480: treatment of steroid-refractory immune checkpoint inhibitor-associated myocarditis: a case series of 18 patients","volume":"84","author":"Jayakrishnan R","year":"2024","unstructured":"Jayakrishnan R, Brongiel S, Luon D, Halene S, Kwan JM. Abstract 2480: treatment of steroid-refractory immune checkpoint inhibitor-associated myocarditis: a case series of 18 patients. Cancer Res. 2024, 84:2480. 10.1158\/1538-7445.am2024-2480","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021210814","article-title":"Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study","volume":"301","author":"Faron A","year":"2021","unstructured":"Faron A, Isaak A, Mesropyan N, et al.. Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study. Radiology. 2021, 301:602-9. 10.1148\/radiol.2021210814","journal-title":"Radiology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang L","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, et al.. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020, 41:1733-43. 10.1093\/eurheartj\/ehaa051","journal-title":"Eur Heart J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier M","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, et al.. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017, 136:2085-7. 10.1161\/CIRCULATIONAHA.117.030571","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-80. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.07.002","article-title":"Steroids in immune checkpoint inhibitor myocarditis","volume":"6","author":"Palaskas NL","year":"2024","unstructured":"Palaskas NL, Siddiqui BA, Deswal A. Steroids in immune checkpoint inhibitor myocarditis. JACC Cardio Oncol. 2024, 6:800-3. 10.1016\/j.jaccao.2024.07.002","journal-title":"JACC Cardio Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang L","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, et al.. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020, 141:2031-4. 10.1161\/CIRCULATIONAHA.119.044703","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem JE","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019, 380:2377-9. 10.1056\/NEJMc1901677","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem JE","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, et al.. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023, 13:1100-15. 10.1158\/2159-8290.CD-22-1180","journal-title":"Cancer Discov"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/424795-fulminant-immune-checkpoint-inhibitor-induced-myocarditis-and-complete-heart-block-in-advanced-melanoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T13:30:16Z","timestamp":1764423016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/424795-fulminant-immune-checkpoint-inhibitor-induced-myocarditis-and-complete-heart-block-in-advanced-melanoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.98075","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}